SMRP-the Swedish study of Metabolic Risk in Psychosis

The purpose of our research is to investigate why people with psychosis often develop metabolic problems such as obesity, type 2 diabetes which are risk factors for cardiovascular disease.

Data and blood samples from people who visit psychosis clinics, mainly in Stockholm, enable us to study genetic, epigenetic and biochemical markers in relation to diagnosis, symptoms and pharmacological treatment.

Team-leaders: Catharina Lavebratt, Martin Schalling

Profile image

Catharina Lavebratt

Principal Researcher

Co-workers in the Translational Psychiatry Group:


Mitochondrial DNA copy number is associated with psychosis severity and anti-psychotic treatment.
Kumar P, Efstathopoulos P, Millischer V, Olsson E, Wei YB, Brüstle O, Schalling M, Villaescusa JC, Ösby U, Lavebratt C
Sci Rep 2018 08;8(1):12743

Plasma GDF15 level is elevated in psychosis and inversely correlated with severity.
Kumar P, Millischer V, Villaescusa JC, Nilsson IAK, Östenson CG, Schalling M, Ösby U, Lavebratt C
Sci Rep 2017 08;7(1):7906

Genetic variants of increased waist circumference in psychosis.
Hukic DS, Ösby U, Olsson E, Hilding A, Östenson CG, Gu HF, Ehrenborg E, Edman G, Schalling M, Lavebratt C, Frisén L
Psychiatr Genet 2017 12;27(6):210-218

Troponin T levels associated with genetic variants in NOTCH2 and MTNR1B in women with psychosis.
Hukic DS, Lavebratt C, Olsson E, Östenson CG, Eriksson SV, Erlinge D, Schalling M, Ösby U
Psychiatry Res 2017 Apr;250():217-220

Content reviewer:
Lilian Pagrot